BACKGROUND: The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society. OBJECTIVE: Members of the European Association of Dermato-Oncology, European Academy of Dermatology and Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereology of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort to emphasize the fundamental role that the specialist in Dermatology-Venereology has in the diagnosis and management of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology. DISCUSSION: Dermatologists play a crucial role in virtually all aspects of skin cancer management including the implementation of primary and secondary prevention, the formation of standardized pathways of care for patients, the establishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the setting up of specific follow-up plans for patients. CONCLUSION: Skin cancers represent an important health issue for modern societies. The role of dermatologists is central to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatology-Venereology.

1st Department of Dermatology Venereology Andreas Sygros Hospital National and Kapodestrian University of Athens Athens Greece

1st Dermatology Department Medical School Aristotle University of Thessaloniki Thessaloniki Greece

2nd Department of Dermatology Venereology ATTIKON Hospital National and Kapodistrian Univeristy of Athens Athens Greece

2nd Department of Dermatology Venerology Papageorgiou Hospital Aristotle University of Thessaloniki Thessaloniki Greece

Center for Dermato oncology Department of Dermatology Eberhard Karls University of Tuebingen Tuebingen Germany

Department Dermatology Environmental Medicine Health Theory University of Osnabrueck Osnabrueck Germany

Department of Cancer Medicine Gustave Roussy Cancer Campus Villejuif France

Department of Dermatolo Cancerology CHU Nantes CIC 1413 CRCINA University Nantes Nantes France

Department of Dermatology and Venereology University Hospital Center Zagreb School of Medicine University of Zagreb Zagreb Croatia

Department of Dermatology AP HP Saint Louis Hospital Paris France

Department of Dermatology Faculty of Medicine Military Medical Academy University of Defense Belgrade Serbia

Department of Dermatology Medical University of Vienna Vienna Austria

Department of Dermatology Toulouse University Toulouse France

Department of Dermatology University Hospital of Bern Inselspital Bern Switzerland

Department of Dermatology University Hospital of Heidelberg Heidelberg Germany

Department of Dermatology University of Kiel Kiel Germany

Department of Dermatology University of Trieste Trieste Italy

Department of Dermatology Venerology and Allergology University Hospital Frankfurt Frankfurt am Main Germany

Department of Dermatovenereology 3rd Faculty of Medicine Charles University University Hospital of Kralovske Vinohrady Prague Czech Republic

Department of General and Oncologic Dermatology Ambroise Paré Hospital APHP and EA 4340 'Biomarkers in Cancerology and Hemato Oncology' UVSQ Université Paris Saclay Boulogne Billancourt France

Department of Oncologic Dermatology University Hospital Elias Carol Davila University of Medicine and Pharmacy Bucharest Romania

Departments of Dermatology University Hospital of Tours Tours France

Departments of Dermatology University Hospital Tübingen Tubingen Germany

Dermatologia Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Dermatologia Università Cattolica del Sacro Cuore Rome Italy

Dermatology Clinic Department of Medical Sciences University of Turin Turin Italy

Dermatology Department Erasme Hospital Université Libre de Bruxelles Brussels Belgium

Dermatology Department Hospital Clinic of Barcelona University of Barcelona Spain

Dermatology Department West Herts NHS Trust London UK

DermoLab Dermatology University of Modena and Reggio Emilia Modena Italy

Faculty of Medicine Centre of Dermatovenereology Clinic of Infectious Diseases and Dermatovenereology Vilnius University Vilnius Lithuania

Institut d'Investigacions Biomédiques August Pi i Sunyer ISCIII Barcelona Spain

Molecular and Pharmaco Epidemiology Unit Department of Experimental Oncology IEO European Institute of Oncology IRCCS Milan Italy

Paris Saclay University Le Kremlin Bicêtre France

Pediatric Dermatology Discipline Dermato oncology Research Facility Colentina Clinical Hospital Bucharest Romania

Timone Hospital Aix Marseille University Marseille France

Twin Research and Genetic Epidemiology Department Kings College London London UK

Zobrazit více v PubMed

Barbaric J, Sekerija M, Agius D et al. Disparities in melanoma incidence and mortality in South-Eastern Europe: Increasing incidence and divergent mortality patterns. Is progress around the corner? Eur J Cancer 1990; 2016: 47-55.

Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 1990; 2018: 108-118.

Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Investig Dermatol 2016; 136: 1161-1171.

Osterlind A. [Non-melanoma skin cancer in Denmark 1943-1982. Cancer statistics no. 15]. Ugeskr. Laeger. 1986; 148; 798-802.

Osterlind A, Moller Jensen O. Trends in incidence of malignant melanoma of the skin in Denmark 1943-1982. Recent Results Cancer Res 1986; 102: 8-17.

Garbe C, Keim U, Eigentler TK et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol 2019; 33: 1272-1280.

Leiter U, Keim U, Eigentler T et al. Incidence, mortality, and trends of nonmelanoma skin cancer in Germany. J Investig Dermatol 2017; 137: 1860-1867.

Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.

Chan TA, Yarchoan M, Jaffee E et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30: 44-56.

Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993; 3: 395-401.

Islami F, Goding Sauer A, Miller KD et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2018; 68: 31-54.

Bordoni A, Leoni-Parvex S, Peverelli S, Mazzola P, Mazzucchelli L, Spitale A. Opportunistic screening strategy for cutaneous melanoma does not change the incidence of nodular and thick lesions nor reduce mortality: a population-based descriptive study in the European region with the highest incidence. Melanoma Res 2013; 23: 402-407.

Elliott TM, Whiteman DC, Olsen CM, Gordon LG. Estimated healthcare costs of melanoma in Australia over 3 years post-diagnosis. Appl Health Econ Health Policy 2017; 15: 805-816.

Guy GP, Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prevent Med 2015; 48; 183-187.

'EUROpe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in research (EUROCOURSE). https://cordis.europa.eu/project/id/219453.

Krensel M, Schäfer I, Zander N, Augustin M. Primary prevention in the context of skin cancer screening. Hautarzt 2019; 70: 432-437.

Kornek T, Augustin M. Skin cancer prevention. J German Soc Dermatol 2013; 11; 283-296; quiz 297-288.

Greinert R, Boniol M. Skin cancer-primary and secondary prevention (information campaigns and screening)-with a focus on children & sunbeds. Prog Biophys Mol Biol 2011; 107: 473-476.

Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.

Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.

Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059.

Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345: e4757.

Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257-263.

Bauer J, Büttner P, Wiecker TS, Luther H, Garbe C. Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 2005; 161: 620-627.

Wiecker TS, Luther H, Buettner P, Bauer J, Garbe C. Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood. Cancer 2003; 97: 628-638.

Stang A, Jockel KH. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer 2016; 122: 432-437.

Lopez AT, Carvajal RD, Geskin L. Secondary prevention strategies for nonmelanoma skin cancer. Oncology 2018; 32: 195-200.

Pérez LL, Bashline B. Skin cancer: prevention. FP Essent 2019; 481: 28-31.

Wernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet] 2016. Rockville (MD): Agency for Healthcare Research and Quality (US); Jul Report No: 14-05210-EF-1 US Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews 2016.

Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: a systematic review. J Am Acad Dermatol 2017; 76: 129-139 e110.

Pennie ML, Soon SL, Risser JB, Veledar E, Culler SD, Chen SC. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol 2007; 143: 488-494.

Aneja S, Aneja S, Bordeaux JS. Association of increased dermatologist density with lower melanoma mortality. Archiv Dermatol 2012; 148: 174-178.

Gordon L, Olsen C, Whiteman DC, Elliott TM, Janda M, Green A. Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study. BMJ Open 2020; 10: e034388.

Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. Eur J Cancer Prevent 2015; 24: 141-149.

Kandel M, Allayous C, Dalle S et al. Update of survival and cost of metastatic melanoma with new drugs: estimations from the MelBase cohort. Eur J Cancer 1990; 2018: 33-40.

Peris K, Fargnoli MC, Garbe C et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019; 118: 10-34.

Garbe C, Amaral T, Peris K et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. Eur J Cancer 2020; 2: 159-177.

Shuber E, Abdulhussein D, Sinclair P, Kadhum M. Who should carry out skin cancer excisions? A systematic review. J Cutan Aesthet Surg 2019; 12: 153-157.

Ramdas K, van Lee C, Beck S et al. Differences in rate of complete excision of basal cell carcinoma by dermatologists, plastic surgeons and general practitioners: a large cross-sectional study. Dermatology 2018; 234: 86-91.

Forsea AM, Del Marmol V, Stratigos A, Geller AC. Melanoma prognosis in Europe: far from equal. Br J Dermatol 2014; 171: 179-182.

Crocetti E, Mallone S, Robsahm TE et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer 2015; 51: 2179-2190.

Minicozzi P, Walsh PM, Sánchez MJ et al. Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis? Eur J Cancer 2018; 93: 127-137.

Forsea AM, Del Marmol V, Geller AC. Priorities and challenges for skin cancer prevention in Europe: an expert survey. Melanoma Res 2013; 23: 298-306.

Forsea AM. Cancer registries in Europe-going forward is the only option. Ecancermedicalscience 2016; 10: 641.

Forsea AM, del Marmol V. Impact, challenges and perspectives of Euromelanoma, a pan-European campaign of skin cancer prevention. J Eur Acad Dermatol Venereol 2013; 27: 1317-1319.

Forsea AM, Tschandl P, Zalaudek I et al. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey. J Eur Acad Dermatol Venereol 2017; 31: 1148-1156.

Kandolf Sekulovic L, Peris K, Hauschild A et al. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. Eur J Cancer 2017; 75: 313-322.

Wouters MW, Michielin O, Bastiaannet E et al. ECCO essential requirements for quality cancer care: melanoma. Crit Rev Oncol Hematol 2018; 122: 164-178.

Garbe C, Amaral T, Peris K et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics - update 2019. Eur J Cancer 2020;126; 141-158.

Stratigos A, Garbe C, Lebbe C et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007.

Lebbe C, Becker JC, Grob J-J et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 1990; 2015: 2396-2403.

Saiag P, Grob JJ, Lebbe C et al. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 2604-2608.

Lebbe C, Garbe C, Stratigos AJ et al. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019; 114: 117-127.

Sirohi B, Chalkidou K, Pramesh CS et al. Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. Lancet Oncol 2018; 19: e395-e406.

Saghatchian M, Thonon F, Boomsma F et al. Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program. J Oncol Pract 2014; 10: e342-e349.

Wouters MW. ECCO essential requirements for quality cancer care for melanoma: defining how to organise care. Eur J Surg Oncol 2018; 44: 381-382.

Kandolf Sekulovic L, Guo J, Agarwala S et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer 2018; 104: 201-209.

Gollnick HPM, Arenberger P, Czarnecka-Operacz M. Training requirements and recommendation for the specialty of dermatology and venereology European Standards of Postgraduate Medical Specialist Training. J Eur Acad Dermatol Venereol. 2019; 33(Suppl 4): 3-25.

Kandolf Sekulovic LPK, Stratigos A, Hauschild A et al. Which medical disciplines diagnose and treat skin cancer in Europe in 2019? A survey in 27 European countries. J Eur Acad Dermatl Venereol, article in preparation.

Robinson SN, Zens MS, Rees JR, Barton DT, Karagas MR. Risk of melanoma following keratinocyte malignancies. Int J Cancer 2020.

Cust AE, Badcock C, Smith J et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol 2020; 182: 1148-1157.

Duarte AF, Sousa-Pinto B, Haneke E, Correia O. Risk factors for development of new skin neoplasms in patients with past history of skin cancer: a survival analysis. Sci Rep 2018; 8: 15744.

Rees JR, Zens MS, Gui J, Celaya MO, Riddle BL, Karagas MR. Non melanoma skin cancer and subsequent cancer risk. PLoS One 2014; 9: e99674.

Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010; 62: 757-767.

Coit DG, Thompson JA, Albertini MR et al. Cutaneous Melanoma, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2019; 17 367-402.

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30: 1884-1901.

Salerni G, Terán T, Puig S et al. Meta-analysis of digital dermoscopy follow-up of melanocytic skin lesions: a study on behalf of the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2013; 27: 805-814.

Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002; 3: 159-165.

European Academy of Dermatology and Venereology. Patient Information Leaflets 2019. URL https://eadv.org/patient-corner/leaflets (last accessed 15 June 2020).

Podlipnik S, Carrera C, Sánchez M et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol 2016; 75: 516-524.

Osella-Abate S, Ribero S, Sanlorenzo M et al. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer 2015; 136: 2453-2457.

Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541-547.

Skaria AM. Diagnostic and surgical accuracy and economic aspects of dermatological surgery - a pilot study. Dermatology 2004; 208: 202-205.

Gualdi G, Monari P, Crotti S et al. Matter of margins. J Eur Acad Dermatol Venereol 2015; 29: 255-261.

Goulding JMR, Levine S, Blizard RA, Deroide F, Swale VJ. Dermatological surgery: a comparison of activity and outcomes in primary and secondary care. Br J Dermatol 2009; 161: 110-114.

Salmon P, Mortimer N, Rademaker M, Adams L, Stanway A, Hill S. Surgical excision of skin cancer: the importance of training. Br J Dermatol 2010; 162: 117-122.

Donaldson MR, Coldiron BM. Dermatologists perform the majority of cutaneous reconstructions in the Medicare population: numbers and trends from 2004 to 2009. J Am Acad Dermatol 2013; 68: 803-808.

Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.

Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.

Scarisbrick JJ, Quaglino P, Prince HM et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181: 350-357.

Pimpinelli N, Olsen EA, Santucci M et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063.

Scarisbrick JJ, Hodak E, Bagot M et al. Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. Eur J Cancer 2018; 101: 278-280.

Quaglino P, Maule M, Prince HM et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2017; 28: 2517-2525.

Trautinger F, Eder J, Assaf C et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017; 77: 57-74.

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl 4): iv30.

Vestergaard T, Prasad SC, Schuster A, Laurinaviciene R, Andersen MK, Bygum A. Diagnostic accuracy and interobserver concordance: teledermoscopy of 600 suspicious skin lesions in Southern Denmark. J Eur Acad Dermatol Venereol 2020; 34: 1601-1608.

Moreno-Ramírez D, Argenziano G. Teledermatology and mobile applications in the management of patients with skin lesions. Acta Dermato Venereol 2017; 218: 31-35.

Mehrtens SH, Shall L, Halpern SM. A 14-year review of a UK teledermatology service: experience of over 40 000 teleconsultations. Clin Exp Dermatol 2019; 44: 874-881.

Marwaha SS, Fevrier H, Alexeeff S et al. Comparative effectiveness study of face-to-face and teledermatology workflows for diagnosing skin cancer. J Am Acad Dermatol 2019; 81: 1099-1106.

Ashrafzadeh S, Nambudiri VE. The COVID-19 crisis: a unique opportunity to expand dermatology to underserved populations. J Am Acad Dermatol 2020; 83: e83-e84.

Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the Era of COVID-19: experience of an academic department of dermatology. J Am Acad Dermatol 2020; 83: e43-e44.

Flaten HK, St Claire C, Schlager E, Dunnick CA, Dellavalle RP. Growth of mobile applications in dermatology - 2017 update. Dermatol Online J 2018; 24: 13030/qt3hs7n9z6.

Freeman K, Dinnes J, Chuchu N et al. Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies. BMJ 2020; 368: m127.

Chung Y, van der Sande AAJ, de Roos KP et al. Poor agreement between the automated risk assessment of a smartphone application for skin cancer detection and the rating by dermatologists. J Eur Acad Dermatol Venereol 2020; 34: 274-278.

Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14: 703-718.

Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 2016; 74: 395-407.

Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199.

Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207-211.

Zeng H, Judson-Torres RL, Shain AH. The evolution of melanoma - moving beyond binary models of genetic progression. J Investig Dermatol 2020; 140: 291-297.

Nirschl CJ, Suárez-Fariñas M, Izar B et al. IFNγ-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 2017; 170: 127-141 e115.

Køster B, Meyer MKH, Søgaard J, Dalum P. Benefit-cost analysis of the danish sun safety campaign 2007-2015: cost savings from sunburn and sunbed use reduction and derived skin cancer reductions 2007-2040 in the Danish Population. PharmacoEcon Open 2019; 2015: 2007-2040.

Koster B, Meyer MKH, Sogaard J, Dalum P. Correction to: benefit-cost analysis of the Danish Sun Safety Campaign 2007-2015: cost savings from sunburn and sunbed use reduction and derived skin cancer reductions 2007-2040 in the Danish Population. Pharmacoecon Open 2019; 2015: 2007-2040.

John SM, Weinert P. Improved Health and Safety at Work by Cooperation with (Social) Partners: A European and Global Perspective. 2016; 151-158.

Ulrich C, Salavastru C, Agner T et al. The European Status Quo in legal recognition and patient-care services of occupational skin cancer. J Eur Acad Dermatol Venereol 2016; 30(Suppl 3): 46-51.

Mitkov M, Chrest M, Diehl NN, Heckman MG, Tollefson M, Jambusaria-Pahlajani A. Pediatric melanomas often mimic benign skin lesions: a retrospective study. J Am Acad Dermatol 2016; 75: 706-711 e704.

Jung GW, Weinstock MA. Clinicopathological comparisons of index and second primary melanomas in paediatric and adult populations. Br J Dermatol 2012; 167: 882-887.

International Commission on Non-Ionizing Radiation P. ICNIRP statement-Protection of workers against ultraviolet radiation. Health Phys 2010; 99: 66-87.

Gisondi P, De Angelis G, Venturelli G, Girolomoni G. Public perception of dermatology and dermatologists in Italy: results from a population-based national survey. J Eur Acad Dermatol Venereol 2017; 31: 2119-2123.

Augustin M, Eissing L, Elsner P et al. Perception and image of dermatology in the German general population 2002-2014. J Eur Acad Dermatol Venereol 2017; 31: 2124-2130.

Richard MA, Joly P, Roy Geffroy B, Taieb C. Public perception of dermatologists in France: results from a population-based national survey. J Eur Acad Dermatol Venereol 2019; 33: 1610-1615.